Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Rezolute, Inc. (RZLT)
USD4.72
-0.11 (-2.28%)
US NASDAQ Healthcare Biotechnology
Address
275 Shoreline Drive 94065
Redwood City, CA, US
Redwood City, CA, US
CEO
Nevan Charles Elam
Website
rezolutebio.com
IPO
2013-01-14
CIK 1509261 ISIN US76200L3096
Description
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.72
-0.11 (-2.28%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.65
Float Shares
65.46M
Free Float %
68.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.91% | +7.77% | -7.76% | -13.28% | -66.50% | +41.10% | -9.26% | +60.10% | -50.00% | -93.06% | -99.31% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (12 ratings, all time)
Buy
Price Targets & DCF
Current price
4.72
Low
2.00
-57.6%
Consensus
6.33
+34.1%
Median
4.50
-4.7%
High
20.00
+323.7%
DCF (Unlevered)
1.15
-75.7%
DCF (Levered)
1.22
-74.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
70% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 6 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 9 |
8.44
+78.8%
|
| All Time | 13 |
7.92
+67.8%
|
Quality scores
Altman Z-Score
16.16
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+26.3% Q1'26: +40.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+47.7% Q1'26: +48.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q1'26: 0.23× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2025 actual |
Jun 2026 6 Rev. Ana. 7 EPS Ana. |
Jun 2027 7 Rev. Ana. 6 EPS Ana. |
Jun 2028 7 Rev. Ana. 6 EPS Ana. |
Jun 2029 3 Rev. Ana. 3 EPS Ana. |
Jun 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
est: 23.49M (-100.0%)
|
385.7K
385.7K – 385.7K
-98.4% YoY
|
3.22M
3.22M – 3.22M
+734.2% YoY
|
62.79M
62.79M – 62.79M
+1,851.3% YoY
|
189.63M
189.63M – 189.63M
+202.0% YoY
|
431.44M
431.44M – 431.44M
+127.5% YoY
|
| EBITDA |
-79.86M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-79.89M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-74.41M
est: -71.20M (-4.5%)
|
-57.73M
-67.07M – -48.39M
+18.9% YoY
|
-55.17M
-56.66M – -53.67M
+4.4% YoY
|
-35.02M
-50.33M – -19.72M
+36.5% YoY
|
-72.50M
-72.50M – -72.50M
-107.0% YoY
|
133.38M
133.38M – 133.38M
+284.0% YoY
|
| SGA |
18.37M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.98
est: -0.92 (-6.2%)
|
-0.76
-0.88 – -0.64
+17.7% YoY
|
-0.73
-0.75 – -0.71
+3.6% YoY
|
-0.43
-0.66 – -0.26
+40.7% YoY
|
-0.95
-0.95 – -0.95
-119.8% YoY
|
1.76
1.76 – 1.76
+284.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
20
Total invested
1.14M
Insider transactions (90d)
0
Beneficial owners (>5%)
30
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Steve Howe | 200.00M | 50.00% | — | 20.00M | — | 10.00 | IN | United States | 2014-01-24 | ↗ |
| 2 | Handok, Inc. | 91.30M | 31.10% | 91.30M | — | 91.30M | 10.00 | CO | South Korea | 2020-03-31 | ↗ |
| 3 | 13G | 8.09M | 13.02% | 8.09M | — | 8.09M | — | CO | State of Delaware | 2018-04-30 | ↗ |
| 4 | Sankaram Mantripragada | 6.53M | 16.10% | 6.53M | — | 6.53M | 10.00 | IN | United States | 2013-02-08 | ↗ |
| 5 | Daniel Mack | 4.12M | 9.90% | — | 4.12M | — | — | HC | USA | 2024-03-11 | ↗ |
| 6 | Nantahala Capital Management, LLC | 4.12M | 9.90% | — | 4.12M | — | — | IA | MA | 2024-03-11 | ↗ |
| 7 | Wilmot B. Harkey | 4.12M | 9.90% | — | 4.12M | — | — | HC | USA | 2024-03-11 | ↗ |
| 8 | Nickolay Kukekov | 3.99M | 9.97% | 2.39M | — | 2.39M | 10.00 | IN | United States | 2013-02-08 | ↗ |
| 9 | Vivo Opportunity Fund Holdings, L.P. | 3.24M | 8.80% | 3.24M | — | 3.24M | — | PN | Delaware | 2023-10-13 | ↗ |
| 10 | Vivo Opportunity, LLC | 3.24M | 8.80% | 3.24M | — | 3.24M | — | OO | Delaware | 2023-10-13 | ↗ |
| 11 | Federated Hermes, Inc. | 3.19M | 20.66% | 3.19M | — | 3.19M | — | HC | Citizenship or place of Organization | 2022-02-14 | ↗ |
| 12 | J. Christopher Donahue | 3.19M | 20.66% | — | 3.19M | — | 3.19M | IN | Citizenship or place of Organization | 2022-02-14 | ↗ |
| 13 | Rhodora J. Donahue | 3.19M | 20.66% | — | 3.19M | — | 3.19M | IN | Citizenship or place of Organization | 2022-02-14 | ↗ |
| 14 | Thomas R. Donahue | 3.19M | 20.66% | — | 3.19M | — | 3.19M | IN | Citizenship or place of Organization | 2022-02-14 | ↗ |
| 15 | Voting Shares Irrevocable Trust | 3.19M | 20.66% | 3.19M | — | 3.19M | — | OO | Citizenship or place of Organization | 2022-02-14 | ↗ |
| 16 | Adage Capital Advisors, L.L.C. | 3.16M | 8.75% | — | 3.16M | — | — | OO | Delaware | 2022-06-27 | ↗ |
| 17 | Adage Capital Partners GP, L.L.C. | 3.16M | 8.75% | — | 3.16M | — | — | OO | Delaware | 2022-06-27 | ↗ |
| 18 | Adage Capital Partners, L.P. | 3.16M | 8.75% | — | 3.16M | — | — | PN | Delaware | 2022-06-27 | ↗ |
| 19 | Phillip Gross | 3.16M | 8.75% | — | 3.16M | — | — | IN | Delaware | 2022-06-27 | ↗ |
| 20 | Robert Atchinson | 3.16M | 8.75% | — | 3.16M | — | — | IN | Delaware | 2022-06-27 | ↗ |
| 21 | First Manhattan Co. LLC | 3.12M | 8.48% | 3.12M | — | 3.12M | — | IA | Delaware | 2023-02-14 | ↗ |
| 22 | Alpha Advisors, LLC (AA) | 2.31M | 12.76% | 1.00 | — | 1.00 | — | IA | Florida | 2014-09-09 | ↗ |
| 23 | Genexine, Inc. | 1.83M | 21.90% | 1.83M | — | 1.83M | 11.00 | CO | — | 2021-07-28 | ↗ |
| 24 | Bruce S. Kovner | 1.33M | 8.60% | — | 1.33M | — | 1.33M | IN | Delaware | 2022-02-14 | ↗ |
| 25 | Caxton Corporation | 1.33M | 8.60% | — | 1.33M | — | 1.33M | CO | Delaware | 2022-02-14 | ↗ |
| 26 | CDK Associates, L.L.C. | 1.25M | 8.00% | — | 1.25M | — | 1.25M | OO | Delaware | 2022-02-14 | ↗ |
| 27 | Jon M. Plexico | 808.4K | 11.00% | 808.4K | — | 808.4K | — | HC, IN | U.S.A. | 2022-02-14 | ↗ |
| 28 | Stonepine Capital Management, LLC | 808.4K | 11.00% | 808.4K | — | 808.4K | — | IA, OO | California | 2022-02-14 | ↗ |
| 29 | Stonepine Capital, L.P. | 808.4K | 11.00% | 808.4K | — | 808.4K | — | PN | Delaware | 2022-02-14 | ↗ |
| 30 | Timothy P. Lynch | 808.4K | 11.00% | 808.4K | — | 808.4K | — | HC, IN | U.S.A. | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
20
-116 vs prev Q
New positions
7
Closed positions
116
Increased
14
Reduced
3
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | FEDERATED HERMES, INC. | 16.53M +2.5M (+17.8%) | 39.02M -92.9M (-70.4%) | 15.99% +1.111 pp | 0.07% -0.168 pp | USD3.72 -36.6% | 21 qtrs — |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 9.18M +9.2M (+100.0%) | 21.66M +21.7M (+100.0%) | 8.85% +8.854 pp | 0.22% +0.222 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 3 | BLACKROCK, INC. | 6.77M +1.8M (+35.2%) | 15.97M -31.1M (-66.0%) | 6.53% +1.223 pp | 0.00% -0.001 pp | USD4.61 -48.8% | 6 qtrs — |
| 4 | OPALEYE MANAGEMENT INC. | 6.29M +5.4M (+595.9%) | 14.84M +6.3M (+74.7%) | 6.06% +5.106 pp | 1.96% +0.757 pp | USD2.69 -12.3% | 6 qtrs — |
| 5 | VANGUARD GROUP INC | 4.79M +378.4K (+8.6%) | 11.30M -30.2M (-72.7%) | 4.62% -0.056 pp | 0.00% -0.001 pp | USD4.54 -48.0% | 19 qtrs — |
| 6 | BALYASNY ASSET MANAGEMENT L.P. | 4.51M +2.7M (+147.3%) | 10.64M -6.5M (-37.9%) | 4.35% +2.415 pp | 0.01% -0.008 pp | USD5.21 -54.7% | 5 qtrs — |
| 7 | BANK OF AMERICA CORP /DE/ | 4.33M +3.0M (+236.6%) | 10.21M -1.9M (-15.5%) | 4.17% +2.809 pp | 0.00% 0.000 pp | USD4.34 -45.6% | 9 qtrs — |
| 8 | STATE STREET CORP | 3.98M +1.9M (+90.4%) | 9.40M -10.3M (-52.2%) | 3.84% +1.623 pp | 0.00% 0.000 pp | USD5.01 -52.9% | 16 qtrs — |
| 9 | UBS GROUP AG | 2.82M +120.3K (+4.5%) | 6.65M -18.7M (-73.8%) | 2.72% -0.142 pp | 0.00% -0.003 pp | USD4.28 -44.9% | 9 qtrs — |
| 10 | AFFINITY ASSET ADVISORS, LLC | 2.35M +251.1K (+12.0%) | 5.55M -14.2M (-71.9%) | 2.27% +0.042 pp | 0.32% -1.403 pp | USD3.02 -21.9% | 8 qtrs — |
| 11 | FMR LLC | 2.31M -10.5M (-81.9%) | 5.44M -114.5M (-95.5%) | 2.22% -11.306 pp | 0.00% -0.006 pp | USD3.67 -35.7% | 4 qtrs — |
| 12 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 2.00M +— (+0.0%) | 4.72M -14.1M (-74.9%) | 1.93% -0.191 pp | 0.23% -1.038 pp | USD5.06 -53.4% | 6 qtrs — |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 1.95M +107.3K (+5.8%) | 4.61M -12.8M (-73.4%) | 1.89% -0.073 pp | 0.00% -0.001 pp | USD4.42 -46.6% | 16 qtrs — |
| 14 | BARCLAYS PLC | 1.91M +1.6M (+517.1%) | 4.51M +1.6M (+54.9%) | 1.84% +1.515 pp | 0.00% +0.000 pp | USD2.68 -11.9% | 5 qtrs — |
| 15 | MILLENNIUM MANAGEMENT LLC | 1.71M +1.5M (+854.5%) | 4.04M +2.4M (+139.6%) | 1.65% +1.460 pp | 0.00% +0.001 pp | USD3.10 -23.9% | 9 qtrs — |
| 16 | VESTAL POINT CAPITAL, LP | 1.69M +1.7M (+100.0%) | 3.98M +4.0M (+100.0%) | 1.63% +1.626 pp | 0.14% +0.135 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 17 | MORGAN STANLEY | 1.52M +1.2M (+348.8%) | 3.58M +402.3K (+12.7%) | 1.46% +1.104 pp | 0.00% +0.000 pp | USD3.05 -22.6% | 13 qtrs — |
| 18 | JANE STREET GROUP, LLC | 1.41M +1.3M (+1,181.9%) | 3.32M +2.3M (+221.8%) | 1.36% +1.241 pp | 0.00% +0.000 pp | USD2.60 -9.2% | 5 qtrs — |
| 19 | GOLDMAN SACHS GROUP INC | 1.30M +763.3K (+141.0%) | 3.08M -2.0M (-39.5%) | 1.26% +0.684 pp | 0.00% 0.000 pp | USD5.12 -53.9% | 4 qtrs — |
| 20 | AMERIPRISE FINANCIAL INC | 1.09M +842.3K (+334.7%) | 2.58M +216.4K (+9.1%) | 1.06% +0.788 pp | 0.00% +0.000 pp | USD2.84 -16.9% | 5 qtrs — |
| 21 | GREAT POINT PARTNERS LLC | 951.8K -1.5M (-61.2%) | 2.25M -20.8M (-90.3%) | 0.92% -1.681 pp | 0.73% -8.776 pp | USD4.44 -46.8% | 5 qtrs — |
| 22 | 22NW, LP | 820.7K +— (+0.0%) | 1.94M -5.8M (-74.9%) | 0.79% -0.078 pp | 0.82% -2.819 pp | USD9.40 -74.9% | 2 qtrs — |
| 23 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | 750.0K +— (+0.0%) | 1.77M -5.3M (-74.9%) | 0.72% -0.072 pp | 1.03% -5.595 pp | USD3.88 -39.2% | 17 qtrs — |
| 24 | NORTHERN TRUST CORP | 737.3K -35.1K (-4.5%) | 1.74M -5.5M (-76.0%) | 0.71% -0.108 pp | 0.00% -0.001 pp | USD5.83 -59.5% | 19 qtrs — |
| 25 | KENNEDY CAPITAL MANAGEMENT LLC | 697.9K +668.7K (+2,291.6%) | 1.65M +1.4M (+500.4%) | 0.67% +0.642 pp | 0.03% +0.029 pp | USD2.65 -10.9% | 2 qtrs — |
| 26 | BANK OF NEW YORK MELLON CORP | 671.7K +480.4K (+251.2%) | 1.59M -212.7K (-11.8%) | 0.65% +0.447 pp | 0.00% 0.000 pp | USD3.33 -29.1% | 3 qtrs — |
| 27 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 665.2K +13.0K (+2.0%) | 1.57M -4.6M (-74.4%) | 0.64% -0.050 pp | 0.00% -0.001 pp | USD7.71 -69.4% | 15 qtrs — |
| 28 | TUDOR INVESTMENT CORP ET AL | 610.0K +610.0K (+100.0%) | 1.44M +1.4M (+100.0%) | 0.59% +0.588 pp | 0.00% +0.003 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 29 | SUPERSTRING CAPITAL MANAGEMENT LP | 513.8K +513.8K (+100.0%) | 1.21M +1.2M (+100.0%) | 0.50% +0.496 pp | 0.65% +0.649 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 30 | XTX TOPCO LTD | 481.9K +457.6K (+1,879.7%) | 1.14M +908.6K (+397.0%) | 0.46% +0.439 pp | 0.03% +0.018 pp | USD2.39 -1.3% | 8 qtrs — |
| 31 | CENTIVA CAPITAL, LP | 407.2K +327.0K (+407.7%) | 961.0K +207.1K (+27.5%) | 0.39% +0.308 pp | 0.01% +0.001 pp | USD3.75 -37.1% | 2 qtrs — |
| 32 | HRT FINANCIAL LP | 374.1K +374.1K (+100.0%) | 882.0K +882.0K (+100.0%) | 0.36% +0.361 pp | 0.00% +0.003 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 33 | WOODLINE PARTNERS LP | 368.2K -570.7K (-60.8%) | 868.9K -8.0M (-90.2%) | 0.36% -0.640 pp | 0.00% -0.038 pp | USD4.70 -49.8% | 6 qtrs — |
| 34 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 354.9K +78.8K (+28.5%) | 837.6K -1.8M (-67.7%) | 0.34% +0.050 pp | 0.00% 0.000 pp | USD3.47 -32.0% | 4 qtrs — |
| 35 | CAPTION MANAGEMENT, LLC | 343.4K -91.9K (-21.1%) | 810.4K -3.3M (-80.2%) | 0.33% -0.130 pp | 0.01% -0.026 pp | USD6.35 -62.8% | 5 qtrs — |
| 36 | KNOTT DAVID M JR | 340.0K +65.0K (+23.6%) | 802.4K -1.8M (-69.0%) | 0.33% +0.037 pp | 0.37% -0.671 pp | USD8.05 -70.7% | 2 qtrs — |
| 37 | STATE OF WISCONSIN INVESTMENT BOARD | 296.8K +296.8K (+100.0%) | 700.5K +700.5K (+100.0%) | 0.29% +0.286 pp | 0.00% +0.002 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 38 | AQR CAPITAL MANAGEMENT LLC | 271.1K +271.1K (+100.0%) | 639.7K +639.7K (+100.0%) | 0.26% +0.261 pp | 0.00% +0.000 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 39 | D. E. SHAW & CO., INC. | 249.4K +249.4K (+100.0%) | 588.6K +588.6K (+100.0%) | 0.24% +0.241 pp | 0.00% +0.000 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 40 | WELLINGTON MANAGEMENT GROUP LLP | 248.7K +21.1K (+9.3%) | 586.9K -1.6M (-72.6%) | 0.24% -0.001 pp | 0.00% 0.000 pp | USD8.80 -73.2% | 2 qtrs — |
| 41 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 209.2K +209.2K (+100.0%) | 493.7K +493.7K (+100.0%) | 0.20% +0.202 pp | 0.12% +0.120 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 42 | PFM HEALTH SCIENCES, LP | 206.3K -246.5K (-54.4%) | 486.8K -3.8M (-88.6%) | 0.20% -0.281 pp | 0.05% -0.279 pp | USD4.66 -49.4% | 3 qtrs — |
| 43 | VIRTU FINANCIAL LLC | 150.6K +150.6K (+100.0%) | 355.0K +355.0K (+100.0%) | 0.15% +0.145 pp | 0.01% +0.014 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 44 | GRAHAM CAPITAL MANAGEMENT, L.P. | 150.0K +150.0K (+100.0%) | 353.9K +353.9K (+100.0%) | 0.14% +0.145 pp | 0.01% +0.009 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 45 | VIRTUS INVESTMENT ADVISERS, INC. | 147.8K +147.8K (+100.0%) | 348.8K +348.8K (+100.0%) | 0.14% +0.143 pp | 0.09% +0.095 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 46 | DIMENSIONAL FUND ADVISORS LP | 141.9K +43.4K (+44.1%) | 334.8K -591.0K (-63.8%) | 0.14% +0.033 pp | 0.00% 0.000 pp | USD3.66 -35.5% | 7 qtrs — |
| 47 | LMR PARTNERS LLP | 140.0K +140.0K (+100.0%) | 330.4K +330.4K (+100.0%) | 0.14% +0.135 pp | 0.00% +0.001 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 48 | RAFFERTY ASSET MANAGEMENT, LLC | 139.4K +86.5K (+163.6%) | 329.0K -168.2K (-33.8%) | 0.13% +0.078 pp | 0.00% -0.001 pp | USD5.03 -53.1% | 2 qtrs — |
| 49 | CITADEL ADVISORS LLC | 127.1K +87.3K (+219.3%) | 300.0K -74.2K (-19.8%) | 0.12% +0.080 pp | 0.00% +0.000 pp | USD3.91 -39.6% | 7 qtrs — |
| 50 | NUVEEN, LLC | 97.7K -210.7K (-68.3%) | 230.5K -2.7M (-92.0%) | 0.09% -0.233 pp | 0.00% -0.001 pp | USD6.63 -64.4% | 3 qtrs — |
| 51 | RHUMBLINE ADVISERS | 96.0K -9.2K (-8.8%) | 226.5K -762.2K (-77.1%) | 0.09% -0.019 pp | 0.00% -0.001 pp | USD4.85 -51.3% | 3 qtrs — |
| 52 | ENGINEERS GATE MANAGER LP | 93.5K +93.5K (+100.0%) | 220.7K +220.7K (+100.0%) | 0.09% +0.090 pp | 0.00% +0.003 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 53 | RENAISSANCE TECHNOLOGIES LLC | 91.5K +91.5K (+100.0%) | 215.8K +215.8K (+100.0%) | 0.09% +0.088 pp | 0.00% +0.000 pp | USD2.36 +0.0% | 15 qtrs — |
| 54 | WELLS FARGO & COMPANY/MN | 89.6K +40.5K (+82.5%) | 211.6K -250.3K (-54.2%) | 0.09% +0.034 pp | 0.00% +0.000 pp | USD4.25 -44.5% | 3 qtrs — |
| 55 | RANGELEY CAPITAL, LLC | 78.2K +78.2K (+100.0%) | 184.6K +184.6K (+100.0%) | 0.08% +0.075 pp | 0.15% +0.153 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 56 | SCIENTECH RESEARCH LLC | 77.8K +77.8K (+100.0%) | 183.7K +183.7K (+100.0%) | 0.08% +0.075 pp | 0.12% +0.116 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 57 | STATE OF ALASKA, DEPARTMENT OF REVENUE | 77.0K +77.0K (+100.0%) | 181.0K +181.0K (+100.0%) | 0.07% +0.075 pp | 0.00% +0.002 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 58 | ALPS ADVISORS INC | 76.1K +33.2K (+77.5%) | 179.7K -223.5K (-55.4%) | 0.07% +0.028 pp | 0.00% -0.001 pp | USD3.77 -37.4% | 5 qtrs — |
| 59 | PERSISTENT ASSET PARTNERS LTD | 72.6K +72.6K (+100.0%) | 171.4K +171.4K (+100.0%) | 0.07% +0.070 pp | 0.08% +0.077 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 60 | ALPHACENTRIC ADVISORS LLC | 67.1K +67.1K (+100.0%) | 158.3K +158.3K (+100.0%) | 0.06% +0.065 pp | 0.16% +0.158 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 61 | DEUTSCHE BANK AG\ | 63.7K +2.9K (+4.8%) | 150.4K -421.1K (-73.7%) | 0.06% -0.003 pp | 0.00% 0.000 pp | USD5.31 -55.6% | 3 qtrs — |
| 62 | SG AMERICAS SECURITIES, LLC | 63.6K +63.6K (+100.0%) | 150.0K +150.0K (+100.0%) | 0.06% +0.062 pp | 0.00% +0.000 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 63 | SHAY CAPITAL LLC | 60.0K +60.0K (+100.0%) | 141.6K +141.6K (+100.0%) | 0.06% +0.058 pp | 0.01% +0.015 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 64 | DECHENG CAPITAL LLC | 59.9K +— (+0.0%) | 141.4K -421.7K (-74.9%) | 0.06% -0.006 pp | 0.02% -0.079 pp | USD4.46 -47.1% | 3 qtrs — |
| 65 | PROFUND ADVISORS LLC | 51.8K +39.5K (+320.1%) | 122.3K +6.4K (+5.5%) | 0.05% +0.037 pp | 0.00% 0.000 pp | USD4.04 -41.6% | 2 qtrs — |
| 66 | NOMURA HOLDINGS INC | 49.8K +49.8K (+100.0%) | 117.5K +117.5K (+100.0%) | 0.05% +0.048 pp | 0.00% +0.000 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 67 | LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 46.4K +46.4K (+100.0%) | 109.5K +109.5K (+100.0%) | 0.04% +0.045 pp | 0.01% +0.007 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 68 | INVESCO LTD. | 45.4K -314.5K (-87.4%) | 107.2K -3.3M (-96.8%) | 0.04% -0.338 pp | 0.00% -0.001 pp | USD8.87 -73.4% | 3 qtrs — |
| 69 | PRICE T ROWE ASSOCIATES INC /MD/ | 45.1K +3.6K (+8.8%) | 107.0K -283.0K (-72.6%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD5.16 -54.3% | 3 qtrs — |
| 70 | QUBE RESEARCH & TECHNOLOGIES LTD | 45.2K +45.2K (+100.0%) | 106.6K +106.6K (+100.0%) | 0.04% +0.044 pp | 0.00% +0.000 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 71 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 45.1K +6.4K (+16.6%) | 105.0K -258.1K (-71.1%) | 0.04% +0.003 pp | 0.00% 0.000 pp | USD4.38 -46.1% | 3 qtrs — |
| 72 | ALLIANCEBERNSTEIN L.P. | 43.9K +— (+0.0%) | 103.5K -308.8K (-74.9%) | 0.04% -0.004 pp | 0.00% 0.000 pp | USD6.67 -64.6% | 3 qtrs — |
| 73 | INTECH INVESTMENT MANAGEMENT LLC | 43.8K +17.6K (+67.1%) | 103.4K -143.1K (-58.0%) | 0.04% +0.015 pp | 0.00% -0.001 pp | USD3.62 -34.8% | 3 qtrs — |
| 74 | METLIFE INVESTMENT MANAGEMENT, LLC | 42.2K +— (+0.0%) | 99.7K -297.3K (-74.9%) | 0.04% -0.004 pp | 0.00% -0.001 pp | USD4.46 -47.1% | 3 qtrs — |
| 75 | ADAR1 CAPITAL MANAGEMENT, LLC | 38.7K -777.3K (-95.3%) | 91.3K -7.6M (-98.8%) | 0.04% -0.828 pp | 0.01% -0.714 pp | USD4.31 -45.2% | 7 qtrs — |
| 76 | SEI INVESTMENTS CO | 37.9K +37.9K (+100.0%) | 89.4K +89.4K (+100.0%) | 0.04% +0.037 pp | 0.00% +0.000 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 77 | JPMORGAN CHASE & CO | 36.9K +3.7K (+11.3%) | 87.2K -224.9K (-72.1%) | 0.04% +0.001 pp | 0.00% +0.000 pp | USD4.46 -47.1% | 3 qtrs — |
| 78 | ACADIAN ASSET MANAGEMENT LLC | 35.3K +35.3K (+100.0%) | 83.0K +83.0K (+100.0%) | 0.03% +0.034 pp | 0.00% +0.000 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 79 | PALE FIRE CAPITAL SE | 33.5K -8.4K (-20.0%) | 79.1K -315.0K (-79.9%) | 0.03% -0.012 pp | 0.01% -0.038 pp | USD4.70 -49.8% | 6 qtrs — |
| 80 | CITIGROUP INC | 32.8K +29.4K (+875.0%) | 77.3K +45.7K (+144.8%) | 0.03% +0.028 pp | 0.00% +0.000 pp | USD2.58 -8.5% | 7 qtrs — |
| 81 | SIG BROKERAGE, LP | 31.0K +31.0K (+100.0%) | 73.2K +73.2K (+100.0%) | 0.03% +0.030 pp | 0.00% +0.002 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 82 | GROUP ONE TRADING, L.P. | 27.7K +26.5K (+2,198.7%) | 65.3K +54.0K (+477.1%) | 0.03% +0.025 pp | 0.00% +0.000 pp | USD2.57 -8.2% | 5 qtrs — |
| 83 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 25.8K -582.0 (-2.2%) | 61.0K -187.3K (-75.4%) | 0.02% -0.003 pp | 0.00% 0.000 pp | USD4.96 -52.4% | 3 qtrs — |
| 84 | DLD ASSET MANAGEMENT, LP | 25.6K -24.4K (-48.8%) | 60.5K -409.2K (-87.1%) | 0.02% -0.028 pp | 0.00% -0.020 pp | USD9.40 -74.9% | 2 qtrs — |
| 85 | NEW YORK STATE COMMON RETIREMENT FUND | 24.6K +— (+0.0%) | 58.1K -173.2K (-74.9%) | 0.02% -0.002 pp | 0.00% 0.000 pp | USD4.72 -50.0% | 3 qtrs — |
| 86 | PANAGORA ASSET MANAGEMENT INC | 22.7K -143.4K (-86.3%) | 53.5K -1.5M (-96.6%) | 0.02% -0.154 pp | 0.00% -0.006 pp | USD9.40 -74.9% | 2 qtrs — |
| 87 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 21.8K +— (+0.0%) | 51.4K -153.5K (-74.9%) | 0.02% -0.002 pp | 0.00% -0.001 pp | USD5.94 -60.3% | 3 qtrs — |
| 88 | WINTON GROUP LTD | 18.5K +18.5K (+100.0%) | 43.7K +43.7K (+100.0%) | 0.02% +0.018 pp | 0.00% +0.002 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 89 | FOX RUN MANAGEMENT, L.L.C. | 17.5K +17.5K (+100.0%) | 41.3K +41.3K (+100.0%) | 0.02% +0.017 pp | 0.01% +0.006 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 90 | IKARIAN CAPITAL, LLC | 16.5K +16.5K (+100.0%) | 38.9K +38.9K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.003 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 91 | JUMP FINANCIAL, LLC | 15.3K +15.3K (+100.0%) | 36.0K +36.0K (+100.0%) | 0.01% +0.015 pp | 0.00% +0.000 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 92 | JEFFERIES FINANCIAL GROUP INC. | 15.0K +15.0K (+100.0%) | 35.4K +35.4K (+100.0%) | 0.01% +0.015 pp | 0.00% +0.000 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 93 | PFG INVESTMENTS, LLC | 15.0K +15.0K (+100.0%) | 35.4K +35.4K (+100.0%) | 0.01% +0.015 pp | 0.00% +0.002 pp | USD2.36 +0.0% | 1 qtrs NEW |
| 94 | PROSHARE ADVISORS LLC | 14.8K +1.5K (+11.6%) | 34.8K -89.5K (-72.0%) | 0.01% +0.000 pp | 0.00% 0.000 pp | USD4.24 -44.3% | 3 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 67 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.73% | 420.7K | 0.65% |
| 2 | Janus Henderson Small Cap Growth Alpha ETF JSML | 0.40% | 1.49M | 0.30% |
| 3 | ALPS Medical Breakthroughs ETF SBIO | 0.23% | 499.5K | 0.50% |
| 4 | iShares Micro-Cap ETF IWC | 0.08% | 1.25M | 0.60% |
| 5 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.05% | 572.8K | 0.20% |
| 6 | Vanguard U.S. Momentum Factor ETF VFMO | 0.05% | 839.2K | 0.13% |
| 7 | Vanguard Global Momentum Factor ETF VMO.TO | 0.05% | 165.6K | 0.38% |
| 8 | Fidelity Enhanced Small Cap ETF FESM | 0.03% | 1.56M | 0.28% |
| 9 | iShares Russell 2000 Value ETF IWN | 0.02% | 2.99M | 0.24% |
| 10 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.01% | 362.4K | 0.30% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.33
Bearish
Ratio by volume
0.20
Bearish
Buys
1
Sells
3
Shares acquired
10.0K
Shares disposed
50.5K
Cash buys
1.00
Cash sales
—
Net activity
-40,495
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-30 | Evans Daron | Officer | P-Purchase | A | Common Shares | 10,000 | 2.85 | 28.5K | 414,462 | D | ↗ |
| 2026-03-02 | ROBERTS BRIAN KENNETH | Officer | F-InKind | D | Common Shares | 11,439 | 2.99 | 34.2K | 296,913 | D | ↗ |
| 2026-03-02 | Evans Daron | Officer | F-InKind | D | Common Shares | 11,438 | 2.99 | 34.2K | 404,462 | D | ↗ |
| 2026-03-02 | Elam Nevan C | Director / Officer | F-InKind | D | Common Shares | 27,618 | 2.99 | 82.6K | 613,501 | D | ↗ |
| 2025-12-16 | ROBERTS BRIAN KENNETH | Officer | P-Purchase | A | Common Shares | 28,000 | 1.70 | 47.6K | 308,352 | D | ↗ |
| 2025-12-16 | Hogenhuis Wladimir | Director | P-Purchase | A | Common Shares | 5,650 | 1.69 | 9.5K | 119,675 | D | ↗ |
| 2025-12-15 | Karnawat Sunil Ratilal | Officer | P-Purchase | A | Common Shares | 12,000 | 1.62 | 19.4K | 71,442 | D | ↗ |
| 2025-12-15 | Evans Daron | Officer | P-Purchase | A | Common Shares | 2,500 | 1.79 | 4.5K | 7,000 | I | ↗ |
| 2025-12-15 | Elam Nevan C | Director / Officer | P-Purchase | A | Common Shares | 32,000 | 1.59 | 50.9K | 641,119 | D | ↗ |
| 2025-12-09 | Evans Daron | Officer | P-Purchase | A | Common Shares | 10,549 | 5.04 | 53.2K | 131,900 | D | ↗ |
| 2025-11-19 | ROBERTS BRIAN KENNETH | Officer | — | A | Employee Stock Option (Right to Buy) | 72,000 | 10.16 | 731.5K | 72,000 | D | ↗ |
| 2025-11-19 | Labrucherie Gil M | Director | A-Award | A | Director Stock Option (Right to Buy) | 12,000 | 10.16 | 121.9K | 12,000 | D | ↗ |
| 2025-11-19 | Kim Young-Jin | Director | A-Award | A | Director Stock Option (Right to Buy) | 12,000 | 10.16 | 121.9K | 12,000 | D | ↗ |
| 2025-11-19 | Karnawat Sunil Ratilal | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 19,000 | 10.16 | 193.0K | 19,000 | D | ↗ |
| 2025-11-19 | KREHER NERISSA | Director | A-Award | A | Director Stock Option (Right to Buy) | 12,000 | 10.16 | 121.9K | 12,000 | D | ↗ |
| 2025-11-19 | Hogenhuis Wladimir | Director | A-Award | A | Common Shares | 21,000 | 0.00 | — | 114,025 | D | ↗ |
| 2025-11-19 | Harris Erik | Director | A-Award | A | Director Stock Option (Right to Buy) | 12,000 | 10.16 | 121.9K | 12,000 | D | ↗ |
| 2025-11-19 | FAUCHET PHILIPPE | Director | A-Award | A | Director Stock Option (Right to Buy) | 12,000 | 10.16 | 121.9K | 12,000 | D | ↗ |
| 2025-11-19 | Evans Daron | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 63,000 | 10.16 | 640.1K | 63,000 | D | ↗ |
| 2025-11-19 | Elam Nevan C | Director / Officer | A-Award | A | Common Shares | 317,000 | 0.00 | — | 609,119 | D | ↗ |
| 2025-08-18 | Karnawat Sunil Ratilal | Officer | — | — | Common Shares | 0 | 0.00 | — | 8,000 | I | ↗ |
| 2025-06-25 | ROBERTS BRIAN KENNETH | Officer | P-Purchase | A | Common Shares | 2,500 | 4.38 | 10.9K | 15,500 | D | ↗ |
| 2025-06-24 | Evans Daron | Officer | P-Purchase | A | Common Shares | 5,000 | 4.05 | 20.3K | 268,900 | D | ↗ |
| 2025-06-13 | Kim Young-Jin | Director | P-Purchase | A | Common Shares | 1,230,769 | 3.25 | 4.00M | 8,423,386 | I | ↗ |
| 2025-06-13 | KREHER NERISSA | Director | P-Purchase | A | Common Shares | 3,076 | 3.25 | 10.0K | 37,576 | D | ↗ |
| 2025-06-10 | ROBERTS BRIAN KENNETH | Officer | A-Award | A | Common Shares | 26,000 | 0.00 | — | 157,352 | D | ↗ |
| 2025-06-10 | Labrucherie Gil M | Director | A-Award | A | Director Stock Option (Right to Buy) | 5,000 | 4.39 | 22.0K | 5,000 | D | ↗ |
| 2025-06-10 | Kim Young-Jin | Director | A-Award | A | Director Stock Option (Right to Buy) | 5,000 | 4.39 | 22.0K | 5,000 | D | ↗ |
| 2025-06-10 | KREHER NERISSA | Director | A-Award | A | Common Shares | 9,000 | 0.00 | — | 34,500 | D | ↗ |
| 2025-06-10 | Hogenhuis Wladimir | Director | A-Award | A | Director Stock Option (Right to Buy) | 5,000 | 4.39 | 22.0K | 5,000 | D | ↗ |
| 2025-06-10 | FAUCHET PHILIPPE | Director | A-Award | A | Director Stock Option (Right to Buy) | 5,000 | 4.39 | 22.0K | 5,000 | D | ↗ |
| 2025-06-10 | Evans Daron | Officer | A-Award | A | Common Shares | 26,000 | 0.00 | — | 263,900 | D | ↗ |
| 2025-06-10 | Elam Nevan C | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 40,000 | 4.39 | 175.6K | 40,000 | D | ↗ |
| 2025-03-31 | Hogenhuis Wladimir | Director | P-Purchase | A | Common Shares | 6,758 | 2.92 | 19.7K | 84,025 | D | ↗ |
| 2025-03-27 | Elam Nevan C | Director / Officer | P-Purchase | A | Common Shares | 12,302 | 2.85 | 35.0K | 224,119 | D | ↗ |
| 2025-03-26 | Evans Daron | Officer | P-Purchase | A | Common Shares | 10,000 | 2.89 | 28.9K | 237,900 | D | ↗ |
| 2025-03-25 | Harris Erik | Director | A-Award | A | Director Stock Option (Right to Buy) | 60,000 | 2.89 | 173.4K | 60,000 | D | ↗ |
| 2025-02-18 | Hogenhuis Wladimir | Director | P-Purchase | A | Common Shares | 10,000 | 4.70 | 47.0K | 77,267 | D | ↗ |
| 2025-02-16 | ROBERTS BRIAN KENNETH | Officer | A-Award | A | Common Shares | 77,000 | 0.00 | — | 131,352 | D | ↗ |
| 2025-02-16 | Labrucherie Gil M | Director | A-Award | A | Director Stock Option (Right to Buy) | 15,000 | 4.61 | 69.2K | 15,000 | D | ↗ |
| 2025-02-16 | Kim Young-Jin | Director | A-Award | A | Common Shares | 25,500 | 0.00 | — | 140,950 | D | ↗ |
| 2025-02-16 | KREHER NERISSA | Director | A-Award | A | Common Shares | 25,500 | 0.00 | — | 25,500 | D | ↗ |
| 2025-02-16 | Hogenhuis Wladimir | Director | A-Award | A | Common Shares | 25,500 | 0.00 | — | 67,267 | D | ↗ |
| 2025-02-16 | FAUCHET PHILIPPE | Director | A-Award | A | Common Shares | 25,500 | 0.00 | — | 25,500 | D | ↗ |
| 2025-02-16 | Evans Daron | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 45,000 | 4.61 | 207.5K | 45,000 | D | ↗ |
| 2025-02-16 | Elam Nevan C | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 120,000 | 4.61 | 553.2K | 120,000 | D | ↗ |
| 2024-12-18 | Evans Daron | Officer | P-Purchase | A | Common Shares | 10,000 | 4.29 | 42.9K | 150,900 | D | ↗ |
| 2024-12-12 | Evans Daron | Officer | P-Purchase | A | Common Shares | 9,000 | 4.60 | 41.4K | 140,900 | D | ↗ |
| 2024-09-24 | Hogenhuis Wladimir | Director | P-Purchase | A | Common Stock | 4,259 | 4.70 | 20.0K | 41,767 | D | ↗ |
| 2024-09-23 | Evans Daron | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 100,000 | 4.79 | 479.0K | 100,000 | D | ↗ |
| 2024-06-25 | Kim Young-Jin | Director | P-Purchase | A | Common Shares | 1,250,000 | 4.00 | 5.00M | 7,192,617 | I | ↗ |
| 2024-06-25 | Hogenhuis Wladimir | Director | P-Purchase | A | Common Stock | 4,815 | 4.15 | 20.0K | 37,508 | — | ↗ |
| 2024-06-14 | ROBERTS BRIAN KENNETH | Officer | P-Purchase | A | Common Shares | 300 | 3.96 | 1.2K | 54,352 | — | ↗ |
| 2024-06-14 | Evans Daron | Officer | P-Purchase | A | Common Shares | 40,000 | 4.04 | 161.6K | 40,000 | — | ↗ |
| 2024-05-29 | Evans Daron | Officer | P-Purchase | A | Common Shares | 451 | 3.50 | 1.6K | 121,351 | — | ↗ |
| 2024-05-24 | Evans Daron | Officer | P-Purchase | A | Common Shares | 2,942 | 3.23 | 9.5K | 13,000 | — | ↗ |
| 2024-05-23 | ROBERTS BRIAN KENNETH | Officer | P-Purchase | A | Common Shares | 6,000 | 2.68 | 16.1K | 50,052 | — | ↗ |
| 2024-05-23 | Evans Daron | Officer | P-Purchase | A | Common Shares | 58 | 2.85 | 165.30 | 10,058 | — | ↗ |
| 2024-03-28 | ROBERTS BRIAN KENNETH | Officer | P-Purchase | A | Common Shares | 500 | 2.55 | 1.3K | 1,076 | — | ↗ |
| 2024-03-15 | Evans Daron | Officer | P-Purchase | A | Common Shares | 20,000 | 1.69 | 33.8K | 20,000 | — | ↗ |
| 2024-03-14 | ROBERTS BRIAN KENNETH | Officer | P-Purchase | A | Common Shares | 10,000 | 1.88 | 18.8K | 10,000 | — | ↗ |
| 2024-03-08 | Evans Daron | Officer | P-Purchase | A | Common Shares | 50,000 | 1.93 | 96.3K | 120,900 | — | ↗ |
| 2024-03-07 | ROBERTS BRIAN KENNETH | Officer | P-Purchase | A | Common Shares | 500 | 1.85 | 925.00 | 576 | — | ↗ |
| 2024-03-07 | Kim Young-Jin | Director | P-Purchase | A | Common Shares | 36,503 | 1.91 | 69.9K | 115,450 | — | ↗ |
| 2024-02-26 | ROBERTS BRIAN KENNETH | Officer | P-Purchase | A | Common Shares | 2,000 | 1.70 | 3.4K | 42,552 | — | ↗ |
| 2024-02-26 | Elam Nevan C | Director / Officer | P-Purchase | A | Common Shares | 5,000 | 1.68 | 8.4K | 7,817 | — | ↗ |
| 2024-02-23 | ROBERTS BRIAN KENNETH | Officer | P-Purchase | A | Common Shares | 6,000 | 1.69 | 10.1K | 40,552 | — | ↗ |
| 2024-02-16 | ROBERTS BRIAN KENNETH | Officer | P-Purchase | A | Common Shares | 7,000 | 1.31 | 9.1K | 34,552 | — | ↗ |
| 2024-02-16 | Evans Daron | Officer | P-Purchase | A | Common Shares | 41,900 | 1.30 | 54.4K | 70,900 | — | ↗ |
| 2024-01-23 | ROBERTS BRIAN KENNETH | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 130,000 | 1.02 | 132.6K | 130,000 | — | ↗ |
| 2024-01-23 | Labrucherie Gil M | Director | A-Award | A | Director Stock Option (Right to Buy) | 30,000 | 1.02 | 30.6K | 30,000 | — | ↗ |
| 2024-01-23 | KREHER NERISSA | Director | A-Award | A | Director Stock Options (Right to Buy) | 30,000 | 1.02 | 30.6K | 30,000 | — | ↗ |
| 2024-01-23 | Hogenhuis Wladimir | Director | A-Award | A | Director Stock Option (Right to Buy) | 30,000 | 1.02 | 30.6K | 30,000 | — | ↗ |
| 2024-01-23 | FAUCHET PHILIPPE | Director | A-Award | A | Director Stock Option (Right to Buy) | 30,000 | 1.02 | 30.6K | 30,000 | — | ↗ |
| 2024-01-23 | Evans Daron | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 275,000 | 1.02 | 280.5K | 275,000 | — | ↗ |
| 2024-01-23 | Elam Nevan C | Director / Officer | A-Award | A | Employee Stock Options (Right to Buy) | 340,000 | 1.02 | 346.8K | 340,000 | — | ↗ |
| 2024-01-22 | Evans Daron | Officer | — | I | Common Shares | 0 | 0.00 | — | 10,000 | — | ↗ |
| 2023-07-03 | ROBERTS BRIAN KENNETH | Officer | P-Purchase | A | Common Shares | 5,000 | 1.90 | 9.5K | 27,552 | — | ↗ |
| 2022-07-22 | Kim Young-Jin | Director | P-Purchase | A | Common Shares | 78,947 | 3.80 | 300.0K | 78,947 | — | ↗ |
| 2022-07-22 | HANDOK, INC. | Director / 10% Owner | P-Purchase | A | Common Shares | 3,157,895 | 3.80 | 12.00M | 5,942,617 | — | ↗ |
| 2022-06-23 | ROBERTS BRIAN KENNETH | Officer | A-Award | A | Stock Option (right to buy) | 700,000 | 0.00 | — | 700,000 | — | ↗ |
| 2022-06-23 | Labrucherie Gil M | Director | A-Award | A | Stock Option (right to buy) | 80,000 | 0.00 | — | 80,000 | — | ↗ |
| 2022-06-23 | Kim Young-Jin | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-06-23 | KREHER NERISSA | Director | A-Award | A | Stock Option (right to buy) | 80,000 | 0.00 | — | 80,000 | — | ↗ |
| 2022-06-23 | Hogenhuis Wladimir | Director | A-Award | A | Stock Option (right to buy) | 80,000 | 0.00 | — | 80,000 | — | ↗ |
| 2022-06-23 | FAUCHET PHILIPPE | Director | A-Award | A | Stock Option (right to buy) | 80,000 | 0.00 | — | 80,000 | — | ↗ |
| 2022-06-23 | Elam Nevan C | Director / Officer | A-Award | A | Stock Option (right to buy) | 2,600,000 | 3.40 | 8.84M | 2,600,000 | — | ↗ |
| 2022-05-17 | ROBERTS BRIAN KENNETH | Officer | P-Purchase | A | Common Stock | 300 | 2.95 | 883.77 | 22,552 | — | ↗ |
| 2022-05-04 | ROBERTS BRIAN KENNETH | Officer | P-Purchase | A | Common Stock | 21,052 | 3.80 | 80.0K | 21,052 | — | ↗ |
| 2022-05-04 | Labrucherie Gil M | Director | P-Purchase | A | Common Stock | 52,631 | 3.80 | 200.0K | 52,631 | — | ↗ |
| 2022-05-04 | Hogenhuis Wladimir | Director | P-Purchase | A | Common Stock | 25,000 | 3.80 | 95.0K | 32,693 | — | ↗ |
| 2021-10-15 | Hogenhuis Wladimir | Director | P-Purchase | A | Common Stock | 7,693 | 6.50 | 50.0K | 7,693 | — | ↗ |
| 2021-10-15 | HANDOK, INC. | Director / 10% Owner | P-Purchase | A | Common Shares | 769,231 | 6.50 | 5.00M | 2,784,722 | — | ↗ |
| 2021-06-14 | ROBERTS BRIAN KENNETH | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 12.28 | 921.0K | 75,000 | — | ↗ |
| 2021-06-14 | Labrucherie Gil M | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 12.28 | 61.4K | 5,000 | — | ↗ |
| 2021-06-14 | KREHER NERISSA | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 12.28 | 122.8K | 10,000 | — | ↗ |
| 2021-06-14 | Hogenhuis Wladimir | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2021-06-14 | FAUCHET PHILIPPE | Director | A-Award | A | Stock Option (right to buy) | 2,000 | 12.28 | 24.6K | 2,000 | — | ↗ |
| 2021-06-14 | Elam Nevan C | Director / Officer | D-Return | D | Stock Option (right to buy) | 70,000 | 60.00 | 4.20M | 0 | — | ↗ |
| 2021-03-03 | KREHER NERISSA | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-03-03 | Hogenhuis Wladimir | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-10-23 | ROBERTS BRIAN KENNETH | Officer | — | — | Employee Stock Option (Right to Buy) | 3,400 | 156.00 | 530.4K | 0 | D | ↗ |
| 2020-10-13 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 2,500 | 23.35 | 58.4K | 2,015,491 | — | ↗ |
| 2020-10-12 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.46 | 58.1K | 100,649,528 | — | ↗ |
| 2020-10-07 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.41 | 50.9K | 100,524,528 | — | ↗ |
| 2020-10-06 | HANDOK, INC. | Director | P-Purchase | A | Common Shares | 125,000 | 0.42 | 52.9K | 100,399,528 | — | ↗ |
| 2020-10-05 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.46 | 57.2K | 100,274,528 | — | ↗ |
| 2020-10-02 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.45 | 56.4K | 100,149,528 | — | ↗ |
| 2020-10-01 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.44 | 55.0K | 100,024,528 | — | ↗ |
| 2020-09-30 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.44 | 54.5K | 99,899,528 | — | ↗ |
| 2020-09-29 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.45 | 55.7K | 99,774,528 | — | ↗ |
| 2020-09-28 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.44 | 55.5K | 99,649,528 | — | ↗ |
| 2020-09-25 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.45 | 55.7K | 99,524,528 | — | ↗ |
| 2020-09-24 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.44 | 55.4K | 99,399,528 | — | ↗ |
| 2020-09-23 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.46 | 57.1K | 99,274,528 | — | ↗ |
| 2020-09-22 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.46 | 57.4K | 99,149,528 | — | ↗ |
| 2020-09-21 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.46 | 57.4K | 99,024,528 | — | ↗ |
| 2020-09-18 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.46 | 57.6K | 98,899,528 | — | ↗ |
| 2020-09-17 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.46 | 57.7K | 98,774,528 | — | ↗ |
| 2020-09-16 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.46 | 57.2K | 98,649,528 | — | ↗ |
| 2020-09-15 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.45 | 56.4K | 98,524,528 | — | ↗ |
| 2020-09-14 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.46 | 57.6K | 98,399,528 | — | ↗ |
| 2020-09-11 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.49 | 61.4K | 98,274,528 | — | ↗ |
| 2020-09-10 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.49 | 61.2K | 98,149,528 | — | ↗ |
| 2020-09-10 | FAUCHET PHILIPPE | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-09-09 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.49 | 61.2K | 98,024,528 | — | ↗ |
| 2020-09-08 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.45 | 56.0K | 97,899,528 | — | ↗ |
| 2020-09-04 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.48 | 60.4K | 97,774,528 | — | ↗ |
| 2020-09-03 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.49 | 60.7K | 97,649,528 | — | ↗ |
| 2020-09-02 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.58 | 72.7K | 97,524,528 | — | ↗ |
| 2020-09-01 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.55 | 69.0K | 97,399,528 | — | ↗ |
| 2020-08-31 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.48 | 60.4K | 97,274,528 | — | ↗ |
| 2020-08-28 | HANDOK, INC. | Director | P-Purchase | A | Common Shares | 125,000 | 0.49 | 61.0K | 97,149,528 | — | ↗ |
| 2020-08-27 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.47 | 58.9K | 97,024,528 | — | ↗ |
| 2020-08-26 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.47 | 58.8K | 96,899,528 | — | ↗ |
| 2020-08-25 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.50 | 62.2K | 96,774,528 | — | ↗ |
| 2020-08-24 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.49 | 61.6K | 96,649,528 | — | ↗ |
| 2020-08-21 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.47 | 59.2K | 96,524,528 | — | ↗ |
| 2020-08-20 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.46 | 56.9K | 96,399,528 | — | ↗ |
| 2020-08-19 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.45 | 56.6K | 96,274,528 | — | ↗ |
| 2020-08-18 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.49 | 61.2K | 96,149,528 | — | ↗ |
| 2020-08-17 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.48 | 59.7K | 96,024,528 | — | ↗ |
| 2020-08-14 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.41 | 51.3K | 95,899,528 | — | ↗ |
| 2020-08-13 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 184,941 | 0.35 | 64.3K | 95,774,528 | — | ↗ |
| 2020-08-12 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.40 | 50.3K | 95,589,587 | — | ↗ |
| 2020-08-11 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.43 | 53.7K | 95,464,587 | — | ↗ |
| 2020-08-10 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.34 | 42.9K | 95,339,587 | — | ↗ |
| 2020-08-07 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.35 | 43.9K | 95,214,587 | — | ↗ |
| 2020-08-06 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.36 | 44.5K | 95,089,587 | — | ↗ |
| 2020-08-05 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.35 | 43.3K | 94,964,587 | — | ↗ |
| 2020-08-04 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.34 | 42.5K | 94,839,587 | — | ↗ |
| 2020-08-03 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.34 | 42.2K | 94,714,587 | — | ↗ |
| 2020-07-31 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 250,000 | 0.31 | 78.7K | 94,589,587 | — | ↗ |
| 2020-07-30 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.32 | 40.3K | 94,339,587 | — | ↗ |
| 2020-07-29 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.34 | 42.0K | 94,214,587 | — | ↗ |
| 2020-07-28 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.32 | 40.6K | 94,089,587 | — | ↗ |
| 2020-07-27 | HANDOK, INC. | Director | P-Purchase | A | Common Shares | 125,000 | 0.34 | 42.2K | 93,964,587 | — | ↗ |
| 2020-07-24 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 125,000 | 0.31 | 39.3K | 93,839,587 | — | ↗ |
| 2020-07-23 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 187,000 | 0.30 | 56.5K | 93,714,587 | — | ↗ |
| 2020-07-22 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 250,000 | 0.28 | 70.8K | 93,527,587 | — | ↗ |
| 2020-07-21 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 250,000 | 0.25 | 63.2K | 93,277,587 | — | ↗ |
| 2020-07-20 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 250,000 | 0.26 | 65.7K | 93,027,587 | — | ↗ |
| 2020-07-17 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 250,000 | 0.21 | 52.2K | 92,777,587 | — | ↗ |
| 2020-07-16 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 250,000 | 0.19 | 46.7K | 92,527,587 | — | ↗ |
| 2020-07-15 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 250,000 | 0.16 | 39.4K | 92,277,587 | — | ↗ |
| 2020-07-14 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 84,000 | 0.16 | 13.2K | 92,027,587 | — | ↗ |
| 2020-07-13 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 100,000 | 0.15 | 15.3K | 91,943,587 | — | ↗ |
| 2020-07-10 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 18,550 | 0.13 | 2.4K | 91,843,587 | — | ↗ |
| 2020-07-09 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 133,804 | 0.13 | 17.3K | 91,825,037 | — | ↗ |
| 2020-07-08 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 45,200 | 0.12 | 5.5K | 91,691,233 | — | ↗ |
| 2020-07-07 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 45,100 | 0.11 | 4.7K | 91,646,033 | — | ↗ |
| 2020-07-06 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Shares | 300,000 | 0.10 | 30.4K | 91,600,933 | — | ↗ |
| 2019-11-20 | Lim Junghee | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-11-20 | Labrucherie Gil M | Director | — | I | Common Shares | 0 | 0.00 | — | 47,042 | — | ↗ |
| 2019-07-31 | Vendola Keith A. | Officer | A-Award | A | Stock Option (right to buy) | 3,000,000 | 0.29 | 870.0K | 3,000,000 | — | ↗ |
| 2019-07-31 | Mantripragada Sankaram | Officer | A-Award | A | Stock Option (right to buy) | 3,500,000 | 0.29 | 1.02M | 3,500,000 | — | ↗ |
| 2019-07-31 | Elam Nevan C | Director / Officer | A-Award | A | Stock Option (right to buy) | 15,000,000 | 0.29 | 4.35M | 15,000,000 | — | ↗ |
| 2019-07-23 | HANDOK, INC. | 10% Owner | P-Purchase | A | Common Stock | 34,482,758 | 0.29 | 10.00M | 91,300,933 | — | ↗ |
| 2019-07-23 | Genexine Inc. | 10% Owner | P-Purchase | A | Common Stock | 34,482,758 | 0.29 | 10.00M | 91,300,933 | — | ↗ |
| 2019-04-26 | HANDOK, INC. | 10% Owner | C-Conversion | D | Series AA Preferred Stock | 1,250,000 | 0.22 | 275.0K | 0 | — | ↗ |
| 2019-04-26 | Genexine Inc. | 10% Owner | C-Conversion | A | Common Stock | 56,818,175 | 0.00 | — | 56,818,175 | — | ↗ |
| 2019-03-04 | Miller Seline E. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-02-11 | Sung Young Chul | Director | — | I | Series AA Preferred Shares | 0 | 0.00 | — | 1,250,000 | — | ↗ |
| 2019-01-30 | HANDOK, INC. | 10% Owner | — | D | Series AA Preferred Stock | 56,818,175 | 0.22 | 12.50M | 0 | — | ↗ |
| 2019-01-30 | Genexine Inc. | 10% Owner | — | D | Series AA Preferred Stock | 56,818,175 | 0.22 | 12.50M | 0 | — | ↗ |
| 2018-05-10 | Vendola Keith A. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-04-23 | XOMA Corp | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 8,093,010 | — | ↗ |
| 2017-03-10 | Welch David F | Director | P-Purchase | A | Common Stock | 5,000 | 0.95 | 4.8K | 1,811,415 | — | ↗ |
| 2017-03-09 | Welch David F | Director | P-Purchase | A | Common Stock | 5,000 | 0.95 | 4.8K | 1,806,415 | — | ↗ |
| 2017-03-08 | Welch David F | Director | P-Purchase | A | Common Stock | 5,000 | 0.98 | 4.9K | 1,801,415 | — | ↗ |
| 2017-03-06 | Welch David F | Director | P-Purchase | A | Common Stock | 5,000 | 0.95 | 4.8K | 1,796,415 | — | ↗ |
| 2017-02-10 | Welch David F | Director | P-Purchase | A | Common Stock | 5,000 | 0.99 | 5.0K | 28,100 | — | ↗ |
| 2017-02-06 | Welch David F | Director | P-Purchase | A | Common Stock | 5,000 | 0.96 | 4.8K | 10,000 | — | ↗ |
| 2017-02-03 | Welch David F | Director | P-Purchase | A | Common Stock | 5,000 | 0.95 | 4.8K | 5,000 | — | ↗ |
| 2017-01-20 | Welch David F | Director | P-Purchase | A | Common Stock | 9,983 | 1.07 | 10.7K | 1,791,415 | — | ↗ |
| 2017-01-19 | Welch David F | Director | P-Purchase | A | Common Stock | 10,000 | 0.95 | 9.5K | 1,781,432 | — | ↗ |
| 2017-01-18 | Welch David F | Director | P-Purchase | A | Common Stock | 5,000 | 1.00 | 5.0K | 1,771,432 | — | ↗ |
| 2017-01-12 | Welch David F | Director | P-Purchase | A | Common Stock | 5,000 | 0.95 | 4.8K | 15,000 | — | ↗ |
| 2017-01-11 | Welch David F | Director | P-Purchase | A | Common Stock | 5,000 | 0.94 | 4.7K | 10,000 | — | ↗ |
| 2017-01-10 | Welch David F | Director | P-Purchase | A | Common Stock | 5,000 | 0.91 | 4.6K | 5,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
95.70M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Nevan Charles Elam Chief Executive Officer | 610.8K | 451.7K | 1.77M | — | — | 21.4K | 2.85M | 61.98% | ↗ |
| 2 | 2025 | Daron Evans Chief Financial Officer | 421.5K | 231.1K | 1.02M | — | — | 46.6K | 1.72M | 59.25% | ↗ |
| 3 | 2025 | Brian Roberts, M.D. Chief Medical Officer | 483.4K | 222.0K | 667.2K | — | — | 62.2K | 1.43M | 46.50% | ↗ |
| 4 | 2024 | Nevan Charles Elam Chief Executive Officer | 550.2K | 342.2K | 277.0K | — | — | 23.3K | 1.19M | 23.23% | ↗ |
| 5 | 2024 | Brian Roberts, M.D. Chief Medical Officer | 471.6K | 195.6K | 105.9K | — | — | 44.9K | 818.0K | 12.95% | ↗ |
| 6 | 2024 | Daron Evans Chief Financial Officer | 121.3K | 59.7K | 201.0K | — | — | 2.0K | 384.1K | 52.34% | ↗ |
| 7 | 2023 | Nevan Charles Elam Chief Executive Officer | 534.1K | 416.1K | — | — | — | 23.5K | 973.6K | 0.00% | ↗ |
| 8 | 2023 | Brian Roberts, M.D. Chief Medical Officer | 457.8K | 237.8K | — | — | — | 43.3K | 738.9K | 0.00% | ↗ |
| 9 | 2022 | Nevan Charles Elam Chief Executive Officer | 1.00 | 4.00 | 5.00 | — | — | 6.00 | 7.78M | 0.00% | ↗ |
| 10 | 2022 | Brian Roberts, M.D. Chief Medical Officer | 2.00 | 4.00 | 5.00 | — | — | 8.00 | 2.42M | 0.00% | ↗ |
| 11 | 2021 | Nevan Elam, Chief Executive Officer | 495.7K | 491.0K | 3.89M | — | — | 22.0K | 4.90M | 79.40% | ↗ |
| 12 | 2021 | Nevan Charles Elam Chief Executive Officer | 495.7K | 491.0K | 3.89M | — | — | 22.0K | 4.90M | 79.40% | ↗ |
| 13 | 2021 | Brian Roberts SVP, Clinical Development | 371.4K | 171.3K | 775.2K | — | — | 36.1K | 1.35M | 57.26% | ↗ |
| 14 | 2021 | Brian Roberts, M.D. Chief Medical Officer | 371.4K | 171.3K | 775.2K | — | — | 36.1K | 1.35M | 57.26% | ↗ |
| 15 | 2021 | Keith Vendola, Former Chief Financial Officer | 244.7K | 166.4K | — | — | — | 206.9K | 618.1K | 0.00% | ↗ |
| 16 | 2020 | Nevan Charles Elam, Chief Executive Officer | 490.0K | 97.0K | 2.69M | — | — | 23.7K | 3.30M | 81.49% | ↗ |
| 17 | 2020 | Nevan Elam, Chief Executive Officer | 490.0K | 97.0K | 2.69M | — | — | 23.7K | 3.30M | 81.49% | ↗ |
| 18 | 2020 | Sankaram Mantripragada, Scientist Emeritus | 350.0K | 57.8K | 627.0K | — | — | 31.9K | 1.07M | 58.78% | ↗ |
| 19 | 2020 | Keith Vendola, Former Chief Financial Officer | 365.0K | 36.1K | 538.0K | — | — | 13.6K | 952.7K | 56.47% | ↗ |
| 20 | 2019 | Keith Vendola, Former Chief Financial Officer | 330.0K | 8.0K | 395.7K | — | — | 1.6K | 735.4K | 53.81% | ↗ |
| 21 | 2019 | Nevan Charles Elam, Chief Executive Officer | 453.3K | 258.8K | — | — | — | 20.2K | 732.2K | 0.00% | ↗ |
| 22 | 2019 | Sankaram Mantripragada, Scientist Emeritus | 350.0K | 181.1K | — | — | — | 31.3K | 562.4K | 0.00% | ↗ |
| 23 | 2018 | Nevan Elam Chief Executive Officer | 450.0K | — | — | 1.91M | — | 18.3K | 2.38M | 80.31% | ↗ |
| 24 | 2018 | Sankaram Mantripragada Chief Scientific Officer | 350.0K | 175.0K | — | 938.3K | — | 18.5K | 1.48M | 63.32% | ↗ |
| 25 | 2018 | Hoyoung Huh Chairman of Scientific Advisory Board and Business Development | 162.0K | — | — | 1.07M | — | 15.1K | 1.24M | 85.75% | ↗ |
| 26 | 2018 | Morgan Fields Chief Accounting Officer | 145.0K | — | — | 282.0K | — | 7.1K | 434.1K | 64.96% | ↗ |
| 27 | 2018 | Keith Vendola Chief Financial Officer | 55.0K | — | — | — | — | 203.00 | 55.2K | 0.00% | ↗ |
| 28 | 2017 | Nevan Elam Chief Executive Officer | 450.0K | 135.0K | — | 1.93M | — | 18.6K | 2.53M | 76.18% | ↗ |
| 29 | 2017 | Hoyoung Huh Chairman of Scientific Advisory Board and Business Development | 216.0K | — | — | 962.6K | — | 18.1K | 1.20M | 80.44% | ↗ |
| 30 | 2017 | Sankaram Mantripragada Chief Scientific Officer | 350.0K | 78.8K | — | 611.3K | — | 30.1K | 1.07M | 57.12% | ↗ |
| 31 | 2017 | Morgan Fields Chief Accounting Officer | 145.0K | 27.2K | — | 266.4K | — | 15.5K | 454.1K | 58.66% | ↗ |
| 32 | 2016 | Nevan Elam Chief Executive Officer | 450.0K | 135.0K | — | 1.75M | — | 18.4K | 2.35M | 74.34% | ↗ |
| 33 | 2016 | Sankaram Mantripragada Chief Scientific Officer | 350.0K | 78.8K | — | 650.7K | — | 25.4K | 1.10M | 58.90% | ↗ |
| 34 | 2016 | Hoyoung Huh Chairman of Scientific Advisory Board and Business Development | 216.0K | — | — | 544.3K | — | 17.9K | 778.2K | 69.94% | ↗ |
| 35 | 2016 | Morgan Fields Chief Accounting Officer | 145.0K | 36.3K | — | 200.6K | — | 13.4K | 395.2K | 50.75% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
| Filing date | Form type | Filing |
|---|---|---|
| 2025-10-07 | DEF 14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Nevan Charles Elam | Founder, Chief Executive Officer, Principal Financial Officer & Acting Chairman of the Board | 1M | male |
| Brian Kenneth Roberts | Chief Medical Officer | 767.5K | — |
| Daron G. Evans | Chief Financial & Business Officer | 699.2K | male |
| Erin O'Boyle | Senior Vice President & Head of Clinical Operations | — | female |
| Melissa Quinn | Senior Director of People and Culture | — | female |
| Michael Covarrubias | Senior Vice President & Head of Program & Portfolio Management | — | male |
| Michael R. Deperro | Senior VP & Head of Operations | — | male |
| Raj Agrawal | Vice President & Head of Ophthalmological Clinical Development | — | — |
| Robyn Sweinhart | Vice President & Head of Quality | — | female |
| Chris Milks | Vice President & Head of Finance | — | male |
| Davelyn Eaves Hood | Director and Head of Scientific & Patient Affairs | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RZLT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
